| Developers: | Foundation Medicine |
| Date of the premiere of the system: | 2020/11/19 |
| Branches: | Internet services, Pharmaceutics, medicine, health care |
Main articles:
2020: Start of the Peer-to-Peer Advice platform
The Roche company announced start in Russia of the information Peer-to-Peer Advice online platform directed to support of adoption of clinical solutions in oncology. It became known on November 19, 2020. The platform gives the chance to the oncologist to address experts of the international level for the recommendation about the strategy of treatment of patients with a malignant new growth on the basis of the report on complex genomic profiling of a tumor.
Complex genomic profiling allows to reveal all clinically significant changes in a tumor genome which lead to development of a disease, once from one sample of biomaterial. The choice of therapy based on such diagnostics is based on a position of the attending physician. But in case of need the doctor can upload the report on complex genomic profiling on the Peer-to-Peer Advice platform and select the expert who will help to analyze data retrieveds and to pick up individual treatment.
The international examination of the Peer-to-Peer platform is provided by specialists from Turkey, to Australia, Austria, Israel and Portugal. The Russian examination is provided by Evgeny Imyanitov managing scientific department of biology of tumoral growth, NMITs of oncology of N.N. Petrov and Valery Breder, the leading researcher of NMITs of oncology of N.N. Blochin. In the future on the platform increase in number of experts for a covering of all requests from the different countries is planned.
 | The nature of changes which happen in a tumor at the molecular and genetic level, defines the choice of therapy from a large number of available options. It is not always simple to correlate observed genomic changes and clinical opportunities. The Peer-to-Peer Advice platform is designed to help the clinical physician to overcome these restrictions, providing access to opinion of recognized experts of the international level as soon as possible to pick up therapy and to help the patient to cope with the illness. |  |
Access to the platform is provided after conclusion of an agreement between medical institution and Roche company. The specialists representing not authorized medical institutions can get access, having sent the patient to the partner medical centers: "European medical center" (Moscow), Medical center "Atlas" (Moscow), TsGRM "Genetiko" (Moscow), MO "Sunrise Clinics" (Anapa), AV Medikal Group (St. Petersburg), "LUCH Clinic" (St. Petersburg).
From the moment of emergence in Russia in 2018 367 patients used service of complex genomic profiling of a tumor in the international Foundation Medicine, Inc. (FMI) technology. The following types of researches are available:
- FoundationOne CDx is diagnostics of genomic changes in 324 genes which can meet in malignant solid tumors.
- FoundationOne Heme is diagnostics of genomic changes more than in 400 genes characteristic of limfoproliferativny diseases and sarcomas.
- FoundationOne Liquid CDx is diagnostics of genomic changes in 324 genes on the basis of the analysis of whole blood, it is applied in cases when the biopsy of fabric is impossible or a sample insufficiently for the analysis and also when progressing a disease.
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |